BibTex RIS Cite

Surgery in the Gastric Cancer: 504 Cases

Year 2014, Volume: 3 Issue: 3, 220 - 225, 01.09.2014
https://doi.org/10.5505/abantmedj.2014.40326

Abstract

OBJECTIVE: Gastric cancer is the second most common cause of cancer-related deaths. It is mostly seen between the ages of 50-70 years. In our study, we aimed to present our 11 years of experience about surgical treatment of gastric cancer.METHODS: In our medical faculty hospital between January 2000 and December 2010, a total of 504 patients, who operated with the diagnosis of gastric cancer, were analyzed retrospectively. Morbidity and mortality rate were evaluated according to type of operations and risk factors.RESULTS: 182 of the patients mean age 62.4 years were female 36.1% and 322 63.9% were male. The tumor location was antrum in the 202 40.1% patients, corpus in the 107 21.2% patients, cardia and fundus in the 195 38.7% patients. Distal subtotal gastrectomy was done 160 %31.7 of the patients, total gastrectomy was done 204 %40.5 of the patients and 140 %27.8 of the patients were considered to be nonresectable because of reasons such as the liver metastasis, peritoneal dissemination and invasion of adjacent organs. Morbidity was found to be %17.6 n=89 and early mortality rate was found as %5.5 n=28 , respectively.CONCLUSION: We found that gastric cancer patients are diagnosed at advanced stage in our region. Especially people who are at risk and have symptoms should be undertaken to screening programs such as endoscopy. In patients with gastric cancer, there is a relationship between advanced age, hypoalbuminemia, and serious co-morbidity with surgical mortality.

References

  • Holburt E, Freedman SI. Gastric carcinoma in patients younger than age 36 years. Cancer. ; 60: 1395-1399.
  • Derici H, Yaman İ, İşgüder AS, Nazlı O, Boz- dağ AD, Tansuğ T. Lokal İleri Evre Mide Kanse- rinde Kombine Rezeksiyonlar. Türkiye Klinikleri J Med Sci 2006, 26: 514-521.
  • Coleman MP, Estève J, Damiecki P, Arslan A, Renard H. Trends in Cancer Incidence and Mor- tality. IARC Sci Publ. 1993; 121: 1-806.
  • Hisamichi S. Screening for gastric cancer. World J Surgery 1989; 13: 31-37.
  • Yüksel BC, Uçar NS, Yıldız Y, Berkem H, Özel H, Hengirmen S. Mide kanserinde standart D2 diseksiyona karşı D1 diseksiyonun mortalite ve morbidite çalışması. Ulusal Cerrahi Dergisi ; 25: 87-91
  • Göçmen E, Kocaoğlu H. Mide kanseri epide- miyolojisi. T Klin J Surg 2000; 5: 161-162.
  • Yalçın B, Zengin N, Aydın F, İlhan M, Işıkdo- ğan A, Demir G ve ark. The clinical and patho- logical features of patients with gastric cancer in Turkey: A Turkish Oncology Group Study. Turkish Journal of Cancer 2006; 36: 108-115.
  • Kama NA, Atlı M, Dağlar G, Yüksek YN, Tü- tüncü T, Reis E. Mide kanserinin cerrahi tedavi- si: 11 yıllık tecrübemiz. Türkiye Klinikleri J Med Sci 2005; 25: 538-545.
  • Maruyama K, Okabayashi K, Kinoshita T. Progress in gastric cancer surgery in Japan and its limits of radicality. World J Surg 1987; 11: 425.
  • Fuchs CS, Mayer RJ. Gastric carcinoma. N Engl J Med 1995; 333: 32-41.
  • Traynor OJ, Lennon J, Dervan P, Corrigan T. Diagnostic and prognostic problems in early gastric cancer. Am J Surg 1987; 154: 516-519.
  • Winn RJ, McClure J. The NCCN clinical prac- tice guidelines in oncology. Gastric cancer. J Nat Compr Cancer Network 2003; 1: 28-29.
  • Sano T, Katai H, Sasako M, Maruyama K. One thousand consecutive gastrectomies wit- hout operative mortality. Br J Surg 2002; 89: 123.
  • Bozzetti F. Rationale for extended lympha- denectomy in gastrectomy for carcinoma. J Am Coll Surg 1995; 180: 505-508.
  • Siewert JR, Böttcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: Ten year results of the German Gastric Cancer Study. Ann Surg 1998; 228: 449-461.
  • Otsuji E, Sawai K, Yamaguchi T, Hagiwara A, Okamoto K, Kobayashi S et al. Resuts of combi- ned complete removal of directly invaded or- gans with the stomach in patients with advan- ced gastric cancer. Hepatogastroenterology ; 49: 1731-1733.
  • Reis E, Doğanay M, Yüksek YN, Atlı M, Kama NA. İlerlemiş mide kanserlerinde genişletilmiş lenf nodu disseksiyonunun yeri ‘klinik prospek- tif çalışma’. T Klin Gastroenterohepatol 2000; : 103-108.
  • Kapan M. Mide kanseri: Tanı ve cerrahi tedavi. İ.Ü. Cerrahpaşa Tıp Fakültesi Sürekli Tıp Eğitimi Etkinlikleri Gastrointestinal Sistem Has- talıkları Sempozyumu. 11-12 Ocak 2001; 253
  • Bozetti F, Marubini E, Bonfanti G, Miceli R, Piano C, Gennari L. Subtotal versus total gast- rectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Italian Gastrointestinal Tumor Study Group. Ann Surg 1999; 230: 170-178.
  • Oñate-Ocaña LF, Aiello-Crocifoglio V, Gal- lardo-Rincón D, Herrera-Goepfert R, Brom- Valladares R, Carrillo JF et al. Serum albumin as a significant prognostic factor for patients with gastric carcinoma. Ann Surg Oncol. 2007; 14: 389.
  • Lien YC, Hsieh CC, Wu YC, Hsu HS, Hsu WH, Wang LS et al. Preoperative serum albumin level is a prognostic indicator for adenocarci- noma of the gastric cardia. J Gastrointest Surg. ; 8: 1041-1048.

Mide Kanserinde Cerrahi: 504 Olgu

Year 2014, Volume: 3 Issue: 3, 220 - 225, 01.09.2014
https://doi.org/10.5505/abantmedj.2014.40326

Abstract

AMAÇ: Mide kanseri kanserle ilişkili ölümlerin en sık ikinci nedenidir ve en çok 50-70 yaş¬ arasında görülür. Çalışmamızda mide kanserlerinin cerrahi tedavisindeki 11 yıllık deneyimlerimizi sunmayı amaçladık.YÖNTEMLER: Çalışmamızda Atatürk Üniversitesi Tıp Fakültesi Hastanesinde Ocak 2000-Aralık 2010 tarihleri arasında mide kanseri tanısı ile opere edilen toplam 504 hastanın verileri retrospektif olarak incelendi. Uygulanan operasyon şekline ve risk fak¬törlerine göre morbidite ve mortalite oranımız değerlendirildi. BULGULAR: Hastaların 182’si kadın %36.1 , 322’si %63.9 erkek ve yaş ortalaması 62.4 yıl idi. Tümör yerleşimi 202 %40.1 hastada antrumda, 107 %21.2 hastada korpusta, 195 % 38.7 hastada kardiya ve fundusta idi. Hastaların 160’ına %31.7 distal subtotal gastrektomi, 204’üne %40.5 total gastrektomi yapılmış ve 140’ında %27.8 ise karaciğer metastazı, peritoneal yayılım ve komşu organ invazyonu gibi nedenlerle tümör nonrezektabl olarak kabul edilmişti. Çalışmamızda morbidite %17.6 n=89 ve erken dönem mortalite oranımız %5.5 n=28 olarak hesaplanmıştır. SONUÇ: Bölgemizde mide kanserli hastaların ileri evrede yakalandığı görülmektedir. Özellikle risk taşıyan ve semptomları olan kişiler, başta endoskopi olmak üze¬re tarama programına alınmalıdır. Mide kanserli hastalarda ileri yaş, hipoalbüminemi ve ciddi komorbidite varlığı ile cerrahi mortalite arasında yakın ilişki vardır.

References

  • Holburt E, Freedman SI. Gastric carcinoma in patients younger than age 36 years. Cancer. ; 60: 1395-1399.
  • Derici H, Yaman İ, İşgüder AS, Nazlı O, Boz- dağ AD, Tansuğ T. Lokal İleri Evre Mide Kanse- rinde Kombine Rezeksiyonlar. Türkiye Klinikleri J Med Sci 2006, 26: 514-521.
  • Coleman MP, Estève J, Damiecki P, Arslan A, Renard H. Trends in Cancer Incidence and Mor- tality. IARC Sci Publ. 1993; 121: 1-806.
  • Hisamichi S. Screening for gastric cancer. World J Surgery 1989; 13: 31-37.
  • Yüksel BC, Uçar NS, Yıldız Y, Berkem H, Özel H, Hengirmen S. Mide kanserinde standart D2 diseksiyona karşı D1 diseksiyonun mortalite ve morbidite çalışması. Ulusal Cerrahi Dergisi ; 25: 87-91
  • Göçmen E, Kocaoğlu H. Mide kanseri epide- miyolojisi. T Klin J Surg 2000; 5: 161-162.
  • Yalçın B, Zengin N, Aydın F, İlhan M, Işıkdo- ğan A, Demir G ve ark. The clinical and patho- logical features of patients with gastric cancer in Turkey: A Turkish Oncology Group Study. Turkish Journal of Cancer 2006; 36: 108-115.
  • Kama NA, Atlı M, Dağlar G, Yüksek YN, Tü- tüncü T, Reis E. Mide kanserinin cerrahi tedavi- si: 11 yıllık tecrübemiz. Türkiye Klinikleri J Med Sci 2005; 25: 538-545.
  • Maruyama K, Okabayashi K, Kinoshita T. Progress in gastric cancer surgery in Japan and its limits of radicality. World J Surg 1987; 11: 425.
  • Fuchs CS, Mayer RJ. Gastric carcinoma. N Engl J Med 1995; 333: 32-41.
  • Traynor OJ, Lennon J, Dervan P, Corrigan T. Diagnostic and prognostic problems in early gastric cancer. Am J Surg 1987; 154: 516-519.
  • Winn RJ, McClure J. The NCCN clinical prac- tice guidelines in oncology. Gastric cancer. J Nat Compr Cancer Network 2003; 1: 28-29.
  • Sano T, Katai H, Sasako M, Maruyama K. One thousand consecutive gastrectomies wit- hout operative mortality. Br J Surg 2002; 89: 123.
  • Bozzetti F. Rationale for extended lympha- denectomy in gastrectomy for carcinoma. J Am Coll Surg 1995; 180: 505-508.
  • Siewert JR, Böttcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: Ten year results of the German Gastric Cancer Study. Ann Surg 1998; 228: 449-461.
  • Otsuji E, Sawai K, Yamaguchi T, Hagiwara A, Okamoto K, Kobayashi S et al. Resuts of combi- ned complete removal of directly invaded or- gans with the stomach in patients with advan- ced gastric cancer. Hepatogastroenterology ; 49: 1731-1733.
  • Reis E, Doğanay M, Yüksek YN, Atlı M, Kama NA. İlerlemiş mide kanserlerinde genişletilmiş lenf nodu disseksiyonunun yeri ‘klinik prospek- tif çalışma’. T Klin Gastroenterohepatol 2000; : 103-108.
  • Kapan M. Mide kanseri: Tanı ve cerrahi tedavi. İ.Ü. Cerrahpaşa Tıp Fakültesi Sürekli Tıp Eğitimi Etkinlikleri Gastrointestinal Sistem Has- talıkları Sempozyumu. 11-12 Ocak 2001; 253
  • Bozetti F, Marubini E, Bonfanti G, Miceli R, Piano C, Gennari L. Subtotal versus total gast- rectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Italian Gastrointestinal Tumor Study Group. Ann Surg 1999; 230: 170-178.
  • Oñate-Ocaña LF, Aiello-Crocifoglio V, Gal- lardo-Rincón D, Herrera-Goepfert R, Brom- Valladares R, Carrillo JF et al. Serum albumin as a significant prognostic factor for patients with gastric carcinoma. Ann Surg Oncol. 2007; 14: 389.
  • Lien YC, Hsieh CC, Wu YC, Hsu HS, Hsu WH, Wang LS et al. Preoperative serum albumin level is a prognostic indicator for adenocarci- noma of the gastric cardia. J Gastrointest Surg. ; 8: 1041-1048.
There are 21 citations in total.

Details

Primary Language Turkish
Journal Section Research Article
Authors

Abdullah Kısaoğlu This is me

Bünyamin Özoğul This is me

Mehmet İlhan Yıldırgan This is me

Sabri Selçuk Atamanalp This is me

Bülent Aydınlı This is me

Gürkan Öztürk This is me

Erdem Karadeniz This is me

Özgür Hakan Bulut This is me

Publication Date September 1, 2014
Published in Issue Year 2014 Volume: 3 Issue: 3

Cite

APA Kısaoğlu, A., Özoğul, B., Yıldırgan, M. İ., Atamanalp, S. S., et al. (2014). Mide Kanserinde Cerrahi: 504 Olgu. Abant Medical Journal, 3(3), 220-225. https://doi.org/10.5505/abantmedj.2014.40326
AMA Kısaoğlu A, Özoğul B, Yıldırgan Mİ, Atamanalp SS, Aydınlı B, Öztürk G, Karadeniz E, Bulut ÖH. Mide Kanserinde Cerrahi: 504 Olgu. Abant Med J. September 2014;3(3):220-225. doi:10.5505/abantmedj.2014.40326
Chicago Kısaoğlu, Abdullah, Bünyamin Özoğul, Mehmet İlhan Yıldırgan, Sabri Selçuk Atamanalp, Bülent Aydınlı, Gürkan Öztürk, Erdem Karadeniz, and Özgür Hakan Bulut. “Mide Kanserinde Cerrahi: 504 Olgu”. Abant Medical Journal 3, no. 3 (September 2014): 220-25. https://doi.org/10.5505/abantmedj.2014.40326.
EndNote Kısaoğlu A, Özoğul B, Yıldırgan Mİ, Atamanalp SS, Aydınlı B, Öztürk G, Karadeniz E, Bulut ÖH (September 1, 2014) Mide Kanserinde Cerrahi: 504 Olgu. Abant Medical Journal 3 3 220–225.
IEEE A. Kısaoğlu, “Mide Kanserinde Cerrahi: 504 Olgu”, Abant Med J, vol. 3, no. 3, pp. 220–225, 2014, doi: 10.5505/abantmedj.2014.40326.
ISNAD Kısaoğlu, Abdullah et al. “Mide Kanserinde Cerrahi: 504 Olgu”. Abant Medical Journal 3/3 (September 2014), 220-225. https://doi.org/10.5505/abantmedj.2014.40326.
JAMA Kısaoğlu A, Özoğul B, Yıldırgan Mİ, Atamanalp SS, Aydınlı B, Öztürk G, Karadeniz E, Bulut ÖH. Mide Kanserinde Cerrahi: 504 Olgu. Abant Med J. 2014;3:220–225.
MLA Kısaoğlu, Abdullah et al. “Mide Kanserinde Cerrahi: 504 Olgu”. Abant Medical Journal, vol. 3, no. 3, 2014, pp. 220-5, doi:10.5505/abantmedj.2014.40326.
Vancouver Kısaoğlu A, Özoğul B, Yıldırgan Mİ, Atamanalp SS, Aydınlı B, Öztürk G, Karadeniz E, Bulut ÖH. Mide Kanserinde Cerrahi: 504 Olgu. Abant Med J. 2014;3(3):220-5.